Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

1.

Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

Grande R, Gemma D, Sperduti I, Gelibter A, Giampaolo MA, Trombetta G, Nelli F, Gamucci T.

Springerplus. 2013 Apr 25;2(1):185. Print 2013 Dec.

PMID:
23667824
[PubMed]
Free PMC Article
2.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.

PMID:
20921462
[PubMed - indexed for MEDLINE]
3.

Chemotherapy of metastatic colorectal cancer.

[No authors listed]

Prescrire Int. 2010 Oct;19(109):219-24. Review.

PMID:
21180382
[PubMed - indexed for MEDLINE]
4.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
[PubMed - indexed for MEDLINE]
5.

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J.

J Clin Oncol. 2007 Oct 20;25(30):4779-86.

PMID:
17947725
[PubMed - indexed for MEDLINE]
6.

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma.

Lam KO, Lee VH, Liu RK, Leung TW, Kwong DL.

Oncol Lett. 2013 Feb;5(2):637-640. Epub 2012 Nov 26.

PMID:
23420587
[PubMed]
Free PMC Article
7.

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K.

Lancet Oncol. 2010 Sep;11(9):853-60. doi: 10.1016/S1470-2045(10)70181-9. Epub 2010 Aug 12.

PMID:
20708966
[PubMed - indexed for MEDLINE]
8.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C.

J Clin Oncol. 2012 Oct 1;30(28):3499-506. Epub 2012 Sep 4.

PMID:
22949147
[PubMed - indexed for MEDLINE]
9.

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer.

Wu Q, Shi Y, Chen L, Xiao X, Dai G.

Onco Targets Ther. 2013 Apr 30;6:485-90. doi: 10.2147/OTT.S41449. Print 2013.

PMID:
23671391
[PubMed]
Free PMC Article
10.

Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.

Chen Y, Cao D, Bi F, Li Q, Qiu M.

Med Oncol. 2014 May;31(5):935. doi: 10.1007/s12032-014-0935-2. Epub 2014 Mar 30.

PMID:
24683007
[PubMed - in process]
11.

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer.

Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H.

Onco Targets Ther. 2013;6:53-8. doi: 10.2147/OTT.S41383. Epub 2013 Jan 25.

PMID:
23378775
[PubMed]
Free PMC Article
12.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

PMID:
18462574
[PubMed - indexed for MEDLINE]
Free Article
13.

Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.

Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK.

Invest New Drugs. 2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28.

PMID:
24468885
[PubMed - in process]
14.

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer.

Louvet C, André T, Gamelin E, Hebbar M, Mabro M, Bennamoun M, Rassam H, de Gramont A.

J Oncol. 2010;2010:785934. doi: 10.1155/2010/785934. Epub 2010 Apr 8.

PMID:
20396391
[PubMed]
Free PMC Article
15.

Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis.

Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP.

Lancet Oncol. 2007 Oct;8(10):898-911. Epub 2007 Sep 20.

PMID:
17888735
[PubMed - indexed for MEDLINE]
16.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R.

Ann Oncol. 2014 Jan;25(1):107-16. doi: 10.1093/annonc/mdt523. Erratum in: Ann Oncol. 2014 Mar;25(3):757.

PMID:
24356622
[PubMed - in process]
17.

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

Bidard FC, Tournigand C, André T, Mabro M, Figer A, Cervantes A, Lledo G, Bengrine-Lefevre L, Maindrault-Goebel F, Louvet C, de Gramont A.

Ann Oncol. 2009 Jun;20(6):1042-7. doi: 10.1093/annonc/mdn730. Epub 2009 Jan 19.

PMID:
19153116
[PubMed - indexed for MEDLINE]
Free Article
18.

Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.

Deng T, Zhang L, Liu XJ, Xu JM, Bai YX, Wang Y, Han Y, Li YH, Ba Y.

Med Oncol. 2013 Dec;30(4):752. doi: 10.1007/s12032-013-0752-z. Epub 2013 Oct 31.

PMID:
24174316
[PubMed - in process]
19.

[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].

Li J, Xu JM, Li J, Zhang XD, Bai Y, Chu YP, Wang YH, Liu DQ, Jin ML, Shen L.

Zhonghua Zhong Liu Za Zhi. 2008 Mar;30(3):225-7. Chinese.

PMID:
18756942
[PubMed - indexed for MEDLINE]
20.

Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer.

Liang HL, Hu AP, Li SL, Liu JY.

Med Oncol. 2014 Jun;31(6):976. doi: 10.1007/s12032-014-0976-6. Epub 2014 May 3.

PMID:
24793617
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk